An Unsymmetrical, Cyclic Diborene Based on a Chelating CAAC Ligand and its Small-Molecule Activation and Rearrangement Chemistry.
Ontology highlight
ABSTRACT:
SUBMITTER: Lu W
PROVIDER: S-EPMC9299934 | biostudies-literature |
REPOSITORIES: biostudies-literature
Similar Datasets
Project description:A cyclic (alkyl)(amino)carbene (CAAC) has been shown to react with a covalent azide similar to the Staudinger reaction. The reaction of Me CAAC with trimethylsilyl azide afforded the N-silylated 2-iminopyrrolidine (Me CAAC=NSiMe3 ), which was fully characterized. This compound undergoes hydrolysis to afford the 2-iminopyrrolidine and trimethylsiloxane which co-crystallize as a hydrogen-bonded adduct. The N-silylated 2-iminopyrrolidine was used to transfer the novel pyrrolidine-2-iminato ligand onto both main-group and transition-metal centers. The reaction of the tetrabromodiborane bis(dimethyl sulfide) adduct with two equivalents of Me CAAC=NSiMe3 afforded the disubstituted diborane. The reaction of Me CAAC=NSiMe3 with TiCl4 and CpTiCl3 afforded Me CAAC=NTiCl3 and Me CAAC=NTiCl2 Cp, respectively.
| S-EPMC7027825 | biostudies-literature
Project description:An investigation on the reactivity of O2 binding to unsymmetrical β-diketiminato copper(I) complexes by spectroscopic and titration analysis was performed. The length of chelating pyridyl arms (pyridylmethyl arm vs pyridylethyl arm) leads to the formation of mono- or di-nuclear copper-dioxygen species at -80 °C. The pyridylmethyl arm adduct (L1CuO2) forms mononuclear copper-oxygen species and shows ligand degradation, resulting in the formation of (2E,3Z)-N-(2,6-diisopropylphenyl)-4-(((E)-pyridin-2-ylmethylene)amino)pent-3-en-2-imine, which slowly converts to its cyclization isomer 1-(2,6-diisopropylphenyl)-4,6-dimethyl-2-(pyridin-2-yl)-1,2-dihydropyrimidine after addition of NH4OH at room temperature. On the other hand, the pyridylethyl arm adduct [(L2Cu)2(μ-O)2] forms dinuclear species at -80 °C and does not show any ligand degradation product. Instead, free ligand formation was observed after the addition of NH4OH. These experimental observations and product analysis results indicate that the chelating length of pyridyl arms governs the Cu/O2 binding ratio and the ligand degradation behavior.
| S-EPMC10268616 | biostudies-literature
Project description:The synthesis of a novel mono-anionic phosphino-amide ligand based on a xanthene backbone is reported, togetherr with the corresponding GaI complex, (PON)Ga (PON = 4-(di(2,4,6-trimethylphenyl)phosphino)-5-(2,6-diisopropylanilido)-2,7-di-tert-butyl-9,9-dimethylxanthene). The solid-state structure of (PON)Ga (obtained from X-ray crystallography) reveals very weak O⋅⋅⋅Ga and P⋅⋅⋅Ga interactions, consistent with a R2 NGa fragment which closely resembles those found in one-coordinate amidogallium systems. Strong N-to-Ga π donation from the amido substituent is reflected in a very short N-Ga distance (1.961(2) Å), while the P⋅⋅⋅Ga contact (3.076(1) Å) is well outside the sum of the respective covalent radii. While the donor properties of the PON ligand towards GaI are highly unsymmetrical, oxidation to GaIII leads to much stronger coordination of the pendant phosphine as shown by P-Ga distances which are up to 20 % shorter. From a steric perspective, the PON ligand is shown to be significantly bulkier than related β-diketiminate systems, a finding consistent with reactions of (PON)Ga towards O-atom sources that proceed without oligomerization. Despite this, the enhanced P-donor properties brought about by oxidation at gallium are not sufficient to quench the reactivity of the highly polar Ga-O unit. Instead, intramolecular benzylic C-H activation is observed across the Ga-O bond of a transient gallanone intermediate.
| S-EPMC7898390 | biostudies-literature
Project description:IPr* (IPr* = 1,3-bis(2,6-bis(diphenylmethyl)-4-methylphenyl)imidazol-2-ylidene) has emerged as a powerful highly hindered and sterically-flexible ligand platform for transition-metal catalysis. CAACs (CAAC = cyclic (al-kyl)(amino)carbenes) have gained major attention as strongly electron-rich carbon analogues of NHCs (NHC = N-heterocyclic carbene) with broad applications in both industry and academia. Herein, we report a merger of CAAC ligands with highly-hindered IPr*. The efficient synthesis, electronic characterization and application in model Cu-catalyzed hydroboration of alkynes is described. The ligands are strongly electron-rich, bulky and flexible around the N-Ar wingtip. The availability of various IPr* and CAAC templates offers a significant potential to expand the existing arsenal of NHC ligands to electron-rich bulky architectures with critical applications in metal stabilization and catalysis.
| S-EPMC9737351 | biostudies-literature
Project description:Regulatory protein-protein interactions are ubiquitous in biology, and small molecule protein-protein interaction inhibitors are an important focus in drug discovery. Remarkably little attention has been given to the opposite strategy-stabilization of protein-protein interactions, despite the fact that several well-known therapeutics act through this mechanism. From a structural perspective, we consider representative examples of small molecules that induce or stabilize the association of protein domains to inhibit, or alter, signaling for nuclear hormone, GTPase, kinase, phosphatase, and ubiquitin ligase pathways. These SPLINTS (small-molecule protein ligand interface stabilizers) drive interactions that are in some cases physiologically relevant, and in others entirely adventitious. The diverse structural mechanisms employed suggest approaches for a broader and systematic search for such compounds in drug discovery.
| S-EPMC4834252 | biostudies-literature
Project description:An expanded family of ruthenium-based metathesis catalysts bearing cyclic alkyl amino carbene (CAAC) ligands was prepared. These catalysts exhibited exceptional activity in the ethenolysis of the seed-oil derivative methyl oleate. In many cases, catalyst turnover numbers (TONs) of more than 100,000 were achieved, at a catalyst loading of only 3?ppm. Remarkably, the most active catalyst system was able to achieve a TON of 340,000, at a catalyst loading of only 1?ppm. This is the first time a series of metathesis catalysts has exhibited such high performance in cross-metathesis reactions employing ethylene gas, with activities sufficient to render ethenolysis applicable to the industrial-scale production of linear ?-olefins (LAOs) and other terminal-olefin products.
| S-EPMC4713124 | biostudies-literature
Project description:Controlling cell fate is essential for embryonic development, tissue regeneration, and the prevention of human disease. With each cell in the human body sharing a common genome, achieving the appropriate spectrum of stem cells and their differentiated lineages requires the selective activation of developmental signaling pathways, the expression of specific target genes, and the maintenance of these cellular states through epigenetic mechanisms. Small molecules that target these regulatory processes are therefore valuable tools for probing and manipulating the molecular mechanisms by which stem cells self-renew, differentiate, and arise from somatic cell reprogramming. Pharmacological modulators of cell fate could also help remediate human diseases caused by dysregulated cell proliferation or differentiation, heralding a new era in molecular therapeutics.
| S-EPMC2807212 | biostudies-other
Project description:Advances in the fields of proteomics, molecular imaging, and therapeutics are closely linked to the availability of affinity reagents that selectively recognize their biological targets. Here we present a review of Iterative Peptide In Situ Click Chemistry (IPISC), a novel screening technology for designing peptide multiligands with high affinity and specificity. This technology builds upon in situ click chemistry, a kinetic target-guided synthesis approach where the protein target catalyzes the conjugation of two small molecules, typically through the azide-alkyne Huisgen cycloaddition. Integrating this methodology with solid phase peptide libraries enables the assembly of linear and branched peptide multiligands we refer to as Protein Catalyzed Capture Agents (PCC Agents). The resulting structures can be thought of as analogous to the antigen recognition site of antibodies and serve as antibody replacements in biochemical and cell-based applications. In this review, we discuss the recent progress in ligand design through IPISC and related approaches, focusing on the improvements in affinity and specificity as multiligands are assembled by target-catalyzed peptide conjugation. We compare the IPISC process to small molecule in situ click chemistry with particular emphasis on the advantages and technical challenges of constructing antibody-like PCC Agents.
| S-EPMC3716466 | biostudies-literature
Project description:Structure-based drug design is frequently used to accelerate the development of small-molecule therapeutics. Although substantial progress has been made in X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, the availability of high-resolution structures is limited owing to the frequent inability to crystallize or obtain sufficient NMR restraints for large or flexible proteins. Computational methods can be used to both predict unknown protein structures and model ligand interactions when experimental data are unavailable. This paper describes a comprehensive and detailed protocol using the Rosetta modeling suite to dock small-molecule ligands into comparative models. In the protocol presented here, we review the comparative modeling process, including sequence alignment, threading and loop building. Next, we cover docking a small-molecule ligand into the protein comparative model. In addition, we discuss criteria that can improve ligand docking into comparative models. Finally, and importantly, we present a strategy for assessing model quality. The entire protocol is presented on a single example selected solely for didactic purposes. The results are therefore not representative and do not replace benchmarks published elsewhere. We also provide an additional tutorial so that the user can gain hands-on experience in using Rosetta. The protocol should take 5-7 h, with additional time allocated for computer generation of models.
| S-EPMC5750396 | biostudies-literature
Project description:Protein domains are evolutionarily conserved building blocks for protein structure and function, which are conventionally identified based on protein sequence or structure similarity. Small molecule binding domains are of great importance for the recognition of small molecules in biological systems and drug development. Many small molecules, including drugs, have been increasingly identified to bind to multiple targets, leading to promiscuous interactions with protein domains. Thus, a large scale characterization of the protein domains and their associations with respect to small-molecule binding is of particular interest to system biology research, drug target identification, as well as drug repurposing. We compiled a collection of 13,822 physical interactions of small molecules and protein domains derived from the Protein Data Bank (PDB) structures. Based on the chemical similarity of these small molecules, we characterized pairwise associations of the protein domains and further investigated their global associations from a network point of view. We found that protein domains, despite lack of similarity in sequence and structure, were comprehensively associated through binding the same or similar small-molecule ligands. Moreover, we identified modules in the domain network that consisted of closely related protein domains by sharing similar biochemical mechanisms, being involved in relevant biological pathways, or being regulated by the same cognate cofactors. A novel protein domain relationship was identified in the context of small-molecule binding, which is complementary to those identified by traditional sequence-based or structure-based approaches. The protein domain network constructed in the present study provides a novel perspective for chemogenomic study and network pharmacology, as well as target identification for drug repurposing.
| S-EPMC3671605 | biostudies-literature